var data={"title":"Acyclovir: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acyclovir: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 25, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is widely used in the treatment of herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). An overview of the mechanisms of action of and resistance to acyclovir and its major clinical uses will be provided here.</p><p>Dosing and treatment of the specific clinical syndromes are described in greater detail on the appropriate topic reviews.</p><p>Use of <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> or <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>, which are later generation agents with a similar mechanism of action, are discussed elsewhere. (See <a href=\"topic.htm?path=valacyclovir-an-overview\" class=\"medical medical_review\">&quot;Valacyclovir: An overview&quot;</a> and <a href=\"topic.htm?path=famciclovir-an-overview\" class=\"medical medical_review\">&quot;Famciclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISM OF ACTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> (9-[2-hydroxymethyl]guanine) is a nucleoside analog that selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV). After intracellular uptake, it is converted to acyclovir monophosphate by virally-encoded thymidine kinase. This step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate by cellular enzymes.</p><p><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> triphosphate competitively inhibits viral DNA polymerase by acting as an analog to deoxyguanosine triphosphate (dGTP). Incorporation of acyclovir triphosphate into DNA results in chain termination since the absence of a 3' hydroxyl group prevents the attachment of additional nucleosides. Acyclovir triphosphate has a much higher affinity for viral DNA polymerase than for the cellular homolog, yielding a high therapeutic ratio [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Spectrum of activity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In descending order of susceptibility, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> is active against HSV types 1 and 2 (HSV-1, HSV-2), VZV, and Epstein-Barr virus (EBV) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Cytomegalovirus (CMV), which does not encode thymidine kinase, is resistant at clinically achievable levels. Activity versus human herpes viruses 6 [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/3\" class=\"abstract_t\">3</a>] and 8 [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/4\" class=\"abstract_t\">4</a>] is similarly limited, and activity versus human herpes virus 7 is not well defined. </p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Mechanism of resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Three mechanisms have been shown to endow herpes simplex viruses with resistance to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, a phenomenon rare in the immunocompetent host [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/5,6\" class=\"abstract_t\">5,6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduced or absent thymidine kinase</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered thymidine kinase activity resulting in decreased <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> phosphorylation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered viral DNA polymerase with decreased affinity for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> triphosphate</p><p/><p><a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a>, which is a prodrug of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, and <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>, which is a prodrug of <a href=\"topic.htm?path=penciclovir-drug-information\" class=\"drug drug_general\">penciclovir</a>, have a similar mechanism of action as acyclovir. Thus, HSV isolates resistant to acyclovir are also resistant to valacyclovir, famciclovir, and penciclovir. (See <a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection#H46\" class=\"medical medical_review\">&quot;Treatment of genital herpes simplex virus infection&quot;, section on 'Antiviral drug resistance'</a>.)</p><p>Resistant herpes simplex viruses have been isolated from a variety of immunocompromised patients, including bone marrow and solid organ transplant recipients and those with the acquired immunodeficiency syndrome (AIDS) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/7\" class=\"abstract_t\">7</a>]. Analysis of isolates from a series of twelve AIDS patients with resistant HSV-2 indicated marked thymidine kinase deficiency in each case; these strains, not surprisingly, were cross-resistant to <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a>, which also requires phosphorylation for antiviral activity. However, <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>, a pyrophosphate analogue, is also a potent inhibitor of HSV DNA polymerase and does not require phosphorylation for its antiviral activity; in clinical trials, foscarnet has demonstrated efficacy in patients with acyclovir-resistant infections [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/8,9\" class=\"abstract_t\">8,9</a>]. (See <a href=\"topic.htm?path=foscarnet-an-overview\" class=\"medical medical_review\">&quot;Foscarnet: An overview&quot;</a>.)</p><p>VZV resistance to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> has been reported in patients with AIDS and other severely immunocompromising conditions. This rare problem usually occurs in the setting of chronic acyclovir therapy and has been linked to mutations in thymidine kinase, resulting in either deficient thymidine kinase or an enzyme with altered substrate specificity [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/5,10\" class=\"abstract_t\">5,10</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">BASIC PHARMACOKINETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> has modest oral bioavailability, about 15 to 30 percent, which decreases with higher doses. As an example, multiple oral doses of 200 to 800 mg yield steady-state peak plasma concentrations of 0.6 to 1.6 <span class=\"nowrap\">mcg/mL,</span> whereas intravenous dosing at 5 to 10 <span class=\"nowrap\">mg/kg</span> every eight hours results in concentrations of 10 to 20 <span class=\"nowrap\">mcg/mL</span>. Thus, the intravenous formulation should be used for serious infections such as disseminated varicella in an immunocompromised host. (See <a href=\"topic.htm?path=treatment-of-varicella-chickenpox-infection#H1944532770\" class=\"medical medical_review\">&quot;Treatment of varicella (chickenpox) infection&quot;, section on 'Immunocompromised hosts'</a>.)</p><p><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is not highly bound to plasma protein (about 15 percent) and achieves widespread tissue and fluid penetration, including the cerebrospinal fluid, in which acyclovir concentrations are approximately 50 percent of those in plasma. (See <a href=\"topic.htm?path=herpes-simplex-virus-type-1-encephalitis#H19\" class=\"medical medical_review\">&quot;Herpes simplex virus type 1 encephalitis&quot;, section on 'Treatment'</a>.)</p><p>Excretion is predominantly renal, both by glomerular filtration and tubular secretion. The plasma half-life is two to three hours in patients with normal renal function; dosage modifications are required in the presence of renal insufficiency, which is a risk factor for acyclovir-related neurotoxicity [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/11,12\" class=\"abstract_t\">11,12</a>]. </p><p>A buccal tablet formulation of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, which is placed on the upper gum (rather than swallowed), was approved by the FDA in 2013 for treatment of recurrent herpes labialis in immunocompetent adults. A single 50 mg tablet yielded a mean salivary concentration of 440 <span class=\"nowrap\">mcg/mL</span> 8 hours after application. However, the plasma concentration of acyclovir that was achieved after administration of the buccal formulation is insufficient to have antiviral activity at non-oral sites [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/13\" class=\"abstract_t\">13</a>]. Thus, the buccal tablet should not be used for the treatment of herpes simplex virus at non-oral sites.</p><p class=\"headingAnchor\" id=\"H20908114\"><span class=\"h1\">DOSE ADJUSTMENTS</span></p><p class=\"headingAnchor\" id=\"H20908121\"><span class=\"h2\">Reduced renal function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dose modification of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> is recommended for patients with a reduced estimated glomerular filtration rate (eGFR) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/14-16\" class=\"abstract_t\">14-16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If administered orally, the dose should be reduced for individuals with an eGFR &le;25 <span class=\"nowrap\">mL/minute/1</span>.73 m<sup>2</sup></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If administered intravenously, the dose should be reduced for individuals with an eGFR &le;50 <span class=\"nowrap\">mL/minute/1</span>.73 m<sup>2 </sup></p><p/><p>Detailed dosing recommendations are available in the <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> drug information monograph included within UpToDate.</p><p class=\"headingAnchor\" id=\"H20908170\"><span class=\"h2\">Obesity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In obese patients (eg, BMI &ge;30), weight-based dosing should be scaled to ideal body weight (IBW) rather than actual body weight (ABW) to avoid an increased risk of toxicity [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/15-19\" class=\"abstract_t\">15-19</a>]. <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is hydrophilic, not highly bound to plasma protein, and distributes mainly into body fluids and non-adipose tissue (see <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above). A calculator to determine IBW (using sex, height, and actual body weight) is available separately in UpToDate (<a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" class=\"calc calc_professional\">calculator 1</a>).</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TOXICITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is remarkably well tolerated in most patients [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/20\" class=\"abstract_t\">20</a>]. There are, however, several important types of toxic reactions.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Acute renal failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acute renal failure, produced by the precipitation of relatively insoluble <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> crystals in the renal tubules, is an occasional complication of intravenous therapy [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/21,22\" class=\"abstract_t\">21,22</a>]. The risk can be minimized by prior hydration (with the urine output maintained above 75 <span class=\"nowrap\">mL/hour)</span> and slow drug infusion over one to two hours [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">&quot;Crystal-induced acute kidney injury (acute renal failure)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Neurologic toxicity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rare reports of neurologic toxicity, particularly in patients with underlying renal failure, have included agitation, tremors, delirium, hallucinations, and myoclonus [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/23\" class=\"abstract_t\">23</a>]. Severe neurotoxicity, characterized by delirium and coma, has been described at doses as low as 800 mg twice daily in patients requiring dialysis [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/24\" class=\"abstract_t\">24</a>]. The potential for this complication is greater in patients treated with peritoneal dialysis, which is associated with minimal removal of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Pharmacokinetic studies suggest that daily doses of 600 to 800 <span class=\"nowrap\">mg/day</span> should lead to safe serum <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> concentrations in patients treated with peritoneal dialysis [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/25\" class=\"abstract_t\">25</a>]. For hemodialysis, a loading dose of 400 mg followed by maintenance dosing of 200 mg twice daily plus 400 mg after each dialysis is recommended [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/26\" class=\"abstract_t\">26</a>]. Patients who develop serious neurotoxicity should be treated with hemodialysis to remove the drug.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">USE IN PREGNANCY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> has been assigned to the US Food and Drug Administration (FDA) Pregnancy Category B in which there is no clear evidence of risk in humans. Although controlled studies have not been performed, several large observational studies have shown reassuring data regarding the safety of acyclovir during pregnancy (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table graphicRef50021 \">table 1</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In an observational cohort of nearly 838,000 live-born infants in Denmark from 1996 to 2008, 1804 pregnancies had been exposed to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, or <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a> during the first trimester of pregnancy [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/27\" class=\"abstract_t\">27</a>]. However, exposure to antiviral therapy was not associated with an increased risk of a birth defect.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Analysis of 1129 pregnancies exposed to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, 712 during the first trimester, from 1984 to 1997, failed to reveal an increase in birth defects when compared with the rate expected in the general population [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/28\" class=\"abstract_t\">28</a>]. </p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">USE OF ACYCLOVIR IN IMMUNOCOMPETENT PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is used for the treatment of herpes simplex virus, herpes zoster, and primary varicella infection in immunocompetent and immunocompromised hosts. It is also occasionally used for postexposure prophylaxis after exposure to varicella. Further information can be found in the appropriate topic selection. </p><p class=\"headingAnchor\" id=\"H620875503\"><span class=\"h1\">IF THERE IS AN ACYCLOVIR SHORTAGE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Shortages of intravenous (IV) <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> have occurred in the United States [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/29,30\" class=\"abstract_t\">29,30</a>]. IV acyclovir is the drug of choice for: neonates with proven herpes simplex virus (HSV) disease, pregnant women with HSV or varicella-zoster virus (VZV) infection, and individuals with herpes simplex encephalitis. During a shortage, IV acyclovir should be reserved for patients with these infections [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/31\" class=\"abstract_t\">31</a>]. However, if IV acyclovir is not available, alternative agents must be used. Clinicians should check the <a href=\"http://www.fda.gov/Drugs/DrugSafety/DrugShortages/&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB815GpcxXHQBvP95J5pU5yOpU7YfF/1DbhN+x+GZZZZpQ==&amp;TOPIC_ID=8332\" target=\"_blank\" class=\"external\">United States Food and Drug Administration</a> and the <a href=\"http://www.ashp.org/menu/DrugShortages/CurrentShortages/Bulletin.aspx?id=467&amp;token=+pHt1hD6PA4yivVRDLB/Em0dOOrxKkhzN36FxSWxnknmyrIaFGuFWFca1CcGvgnSDzUHd/hYkWHeY5gA3gbv0Gj4BhESFd1/q5eGK7H1fKc=&amp;TOPIC_ID=8332\" target=\"_blank\" class=\"external\">American Society of Health-system pharmacists</a> websites for information about the availability of IV acyclovir.</p><p class=\"headingAnchor\" id=\"H693179357\"><span class=\"h2\">Overview of alternative agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Guidance on the management and treatment of these various infections when a shortage occurs is listed below. Consultation with an infectious disease specialist is recommended. All dosing recommendations for the antiviral agents listed below are for patients with normal renal function; dosage adjustments are required for patients with renal insufficiency.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">Ganciclovir</a> &#9472; Ganciclovir is an acyclic analog of the nucleoside guanosine that has established antiviral efficacy in the treatment of cytomegalovirus infections. Ganciclovir also inhibits the replication of other herpesviruses in vitro, including HSV-1 and HSV-2; however, there are few clinical data on the use of this antiviral medication for the clinical indications listed above.</p><p/><p class=\"bulletIndent1\">Clinicians need to be aware that <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> is associated with more toxicity than <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>, particularly bone marrow suppression (anemia, leukopenia <span class=\"nowrap\">and/or</span> thrombocytopenia). Hematologic monitoring is recommended in patients receiving ganciclovir. Ganciclovir should be used in pregnancy only if the potential benefit outweighs the potential risk to the fetus. (See <a href=\"topic.htm?path=ganciclovir-and-valganciclovir-an-overview\" class=\"medical medical_review\">&quot;Ganciclovir and valganciclovir: An overview&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> &#9472; Foscarnet has been associated with decreased renal function and electrolyte abnormalities. Monitoring of renal function and electrolytes is recommended in patients taking foscarnet. In addition, patients should receive prehydration with normal saline before each dose of foscarnet. The concomitant administration of other nephrotoxic agents should be avoided, when possible. (See <a href=\"topic.htm?path=foscarnet-an-overview#H6\" class=\"medical medical_review\">&quot;Foscarnet: An overview&quot;, section on 'Toxicity'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=cidofovir-drug-information\" class=\"drug drug_general\">Cidofovir</a> &#9472; Cidofovir does not cross the blood-brain barrier and should <strong>not</strong> be substituted for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> in patients with central nervous system infections. <br/></p><p class=\"headingAnchor\" id=\"H273810246\"><span class=\"h2\">Management of clinical conditions when IV acyclovir is unavailable</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Herpes simplex encephalitis</strong> &mdash; For suspected or documented HSV encephalitis we administer <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (for infants &le;90 days old: 6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 <span class=\"nowrap\">mg/kg</span> every 12 hours) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/31\" class=\"abstract_t\">31</a>]. If ganciclovir cannot be given, we suggest <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> (for infants and children: 60 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for adults: 90 <span class=\"nowrap\">mg/kg</span> IV every 12 hours or 60 <span class=\"nowrap\">mg/kg</span> IV every 8 hours). (See <a href=\"topic.htm?path=herpes-simplex-virus-type-1-encephalitis#H19\" class=\"medical medical_review\">&quot;Herpes simplex virus type 1 encephalitis&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neonatal herpes simplex infection</strong> &mdash; For suspected neonatal HSV infection we suggest <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (for infants &le;90 days old: 6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for infants &gt;90 days old: 5 <span class=\"nowrap\">mg/kg</span> every 12 hours) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/31\" class=\"abstract_t\">31</a>]. If ganciclovir cannot be given, we suggest <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> (60 <span class=\"nowrap\">mg/kg</span> IV every 12 hours). The duration of treatment is the same as it would be for <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. </p><p/><p class=\"bulletIndent1\">Patients should be monitored closely for response to therapy because there is a lack of clinical experience with <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> for the treatment of neonatal HSV; this includes repeat sampling of cerebrospinal fluid for HSV PCR. (See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-management-and-prevention\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Management and prevention&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Varicella pneumonia</strong> &mdash; For patients with suspected or documented varicella pneumonia we suggest <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (for infants &lt;90 days old: 6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 <span class=\"nowrap\">mg/kg</span> IV every 12 hours) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/31\" class=\"abstract_t\">31</a>]. If ganciclovir cannot be given, we suggest <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> (for infants and children: 60 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for adults: 90 <span class=\"nowrap\">mg/kg</span> IV every 12 hours or 60 <span class=\"nowrap\">mg/kg</span> IV every 8 hours). <br/><br/>Adults who have improved on IV ganciclovir can be switched to a high dose of oral <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (in adults: 2000 mg four times daily) provided that they are expected to absorb oral medications adequately. In adults who are not severely ill, it is reasonable to give a lower dose of valacyclovir (1000 mg three times daily). We do not recommend oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> in this situation since it is not highly bioavailable. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Disseminated herpes simplex virus infection</strong> &mdash; HSV infection can cause disseminated disease in immunocompromised and immunocompetent hosts. For infants or for immunocompromised <span class=\"nowrap\">and/or</span> severely ill children and adults, we suggest <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (for infants &lt;90 days old: 6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 <span class=\"nowrap\">mg/kg</span> IV every 12 hours) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/31\" class=\"abstract_t\">31</a>]. If ganciclovir cannot be given, we suggest <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> (for infants and children: 60 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for adults: 90 <span class=\"nowrap\">mg/kg</span> IV every 12 hours or 60 <span class=\"nowrap\">mg/kg</span> IV every 8 hours). Adults who are improving on IV therapy can be switched to <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1000 mg orally three times daily). <br/></p><p class=\"bulletIndent1\">For immunocompetent children or adults who are not severely ill (eg, patients experiencing their initial HSV episode, who may have lesions distant from the site of inoculation), we suggest initial therapy with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (for children: 20 <span class=\"nowrap\">mg/kg</span> per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Disseminated herpes zoster infection</strong> &mdash; Varicella-zoster virus infection can cause disseminated disease in immunocompromised and immunocompetent hosts. For immunocompromised patients or severely ill patients, we suggest <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (for infants &lt;90 days old: 6 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for infants &gt;90 days old, children, and adults: 5 <span class=\"nowrap\">mg/kg</span> IV every 12 hours) [<a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/31\" class=\"abstract_t\">31</a>]. If ganciclovir cannot be given, we suggest <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> (for infants and children: 60 <span class=\"nowrap\">mg/kg</span> IV every 12 hours; for adults: 90 <span class=\"nowrap\">mg/kg</span> IV every 12 hours or 60 <span class=\"nowrap\">mg/kg</span> IV every 8 hours). Patients who are improving on IV therapy can be switched to <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (for children: 20 <span class=\"nowrap\">mg/kg</span> per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily).</p><p/><p class=\"bulletIndent1\">For immunocompetent patients who are not severely ill, we suggest initial therapy with <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (for children: 20 <span class=\"nowrap\">mg/kg</span> per dose orally three times daily [maximum dose 1000 mg per dose]; for adults: 1000 mg orally three times daily). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Esophageal herpes simplex infection</strong> &mdash; For patients with HSV esophagitis who are unable to take medications orally due to odynophagia, we suggest <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (5 <span class=\"nowrap\">mg/kg</span> IV every 12 hours). If ganciclovir cannot be given, we suggest <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> (40 <span class=\"nowrap\">mg/kg</span> IV every 8 to 12 hours). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mucocutaneous herpes simplex infections</strong> &mdash; Immunocompetent patients with mucocutaneous HSV infection can be treated with oral <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>, or <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a>, or <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Prophylaxis against HSV or VZV infections in transplant recipients</strong> &mdash; For prophylaxis against HSV or VZV infections in adult transplant recipients, we suggest <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1000 mg two times daily) or <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a> (500 mg twice daily). For patients who cannot take oral agents, we suggest <a href=\"topic.htm?path=ganciclovir-drug-information\" class=\"drug drug_general\">ganciclovir</a> (5 <span class=\"nowrap\">mg/kg</span> IV once daily).</p><p/><p class=\"headingAnchor\" id=\"H28068474\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is widely used in the treatment of herpesvirus infections, particularly herpes simplex virus (HSV) and varicella-zoster virus (VZV). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After intracellular uptake, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> is converted to acyclovir monophosphate by virally-encoded thymidine kinase; this step does not occur to any significant degree in uninfected cells and thereby lends specificity to the drug's activity. The monophosphate derivative is subsequently converted to acyclovir triphosphate, which leads to DNA chain termination. (See <a href=\"#H2\" class=\"local\">'Mechanism of action'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acyclovir-resistant herpes simplex viruses have been isolated from a variety of immunocompromised patients, including bone marrow and solid organ transplant recipients and those with the acquired immunodeficiency syndrome (AIDS). However, acyclovir-resistant herpes viruses are rarely detected in the immunocompetent host. Clinicians need to be aware that herpes simplex viral isolates that are resistant to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> are also resistant to <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> and <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>. <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">Foscarnet</a> can be effective in this clinical scenario. (See <a href=\"#H4\" class=\"local\">'Mechanism of resistance'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The oral formulation of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> has modest oral bioavailability; thus, the intravenous formulation should be used for serious infections, such as disseminated varicella in an immunocompromised host. (See <a href=\"#H5\" class=\"local\">'Basic pharmacokinetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is generally well tolerated. (See <a href=\"#H6\" class=\"local\">'Toxicity'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although no controlled studies among pregnant women have been performed, large observational studies have suggested that <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> use during the first trimester of pregnancy is not associated with an increased risk of teratogenicity. (See <a href=\"#H9\" class=\"local\">'Use in pregnancy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Shortages of intravenous <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> have occurred in the United States. The use of alternative antivirals for certain clinical manifestations is described above. (See <a href=\"#H620875503\" class=\"local\">'If there is an acyclovir shortage'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/1\" class=\"nounderline abstract_t\">Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992; 327:782.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/2\" class=\"nounderline abstract_t\">Hirsch MS, Swartz MN. Drug therapy: antiviral agents (second of two parts). N Engl J Med 1980; 302:949.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/3\" class=\"nounderline abstract_t\">Amjad M, Gillespie MA, Carlson RM, Karim MR. Flow cytometric evaluation of antiviral agents against human herpesvirus 6. Microbiol Immunol 2001; 45:233.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/4\" class=\"nounderline abstract_t\">Coen N, Duraffour S, Topalis D, et al. Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses. Antimicrob Agents Chemother 2014; 58:7312.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/5\" class=\"nounderline abstract_t\">Chatis PA, Crumpacker CS. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 1992; 36:1589.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/6\" class=\"nounderline abstract_t\">Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/7\" class=\"nounderline abstract_t\">Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112:416.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/8\" class=\"nounderline abstract_t\">Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/9\" class=\"nounderline abstract_t\">Hardy WD. Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. Am J Med 1992; 92:30S.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/10\" class=\"nounderline abstract_t\">Boivin G, Edelman CK, Pedneault L, et al. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 1994; 170:68.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/11\" class=\"nounderline abstract_t\">Laskin OL. Clinical pharmacokinetics of acyclovir. Clin Pharmacokinet 1983; 8:187.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/12\" class=\"nounderline abstract_t\">Adair JC, Gold M, Bond RE. Acyclovir neurotoxicity: clinical experience and review of the literature. South Med J 1994; 87:1227.</a></li><li class=\"breakAll\">Sitavig (acyclovir) buccal tablets prescribing information. Farmea, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203791s000lbl.pdf (Accessed on December 09, 2014).</li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/14\" class=\"nounderline abstract_t\">Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29:562.</a></li><li class=\"breakAll\">Acyclovir tablet, capsule, and oral suspension United States Prescribing information (revised July, 2013); available at US National Library of Medicine DailyMed website http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f94a46a2-2e86-4d98-ec89-9483a41d290a.</li><li class=\"breakAll\">Acyclovir sodium injection; United States prescribing information (revised May, 2014); available at US National Library of Medicine DailyMed website available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=badf347b-eeee-4239-9c74-966f262925aa.</li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/17\" class=\"nounderline abstract_t\">Hernandez JO, Norstrom J, Wysock G. Acyclovir-induced renal failure in an obese patient. Am J Health Syst Pharm 2009; 66:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/18\" class=\"nounderline abstract_t\">Polso AK, Lassiter JL, Nagel JL. Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review. J Clin Pharm Ther 2014; 39:584.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/19\" class=\"nounderline abstract_t\">Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997; 25:112.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/20\" class=\"nounderline abstract_t\">Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/21\" class=\"nounderline abstract_t\">Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med 1988; 84:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/22\" class=\"nounderline abstract_t\">Perazella MA. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325:349.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/23\" class=\"nounderline abstract_t\">Feldman S, Rodman J, Gregory B. Excessive serum concentrations of acyclovir and neurotoxicity. J Infect Dis 1988; 157:385.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/24\" class=\"nounderline abstract_t\">Davenport A, Goel S, Mackenzie JC. Neurotoxicity of acyclovir in patients with end-stage renal failure treated with continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1992; 20:647.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/25\" class=\"nounderline abstract_t\">Stathoulopoulou F, Almond MK, Dhillon S, Raftery MJ. Clinical pharmacokinetics of oral acyclovir in patients on continuous ambulatory peritoneal dialysis. Nephron 1996; 74:337.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/26\" class=\"nounderline abstract_t\">Almond MK, Fan S, Dhillon S, et al. Avoiding acyclovir neurotoxicity in patients with chronic renal failure undergoing haemodialysis. Nephron 1995; 69:428.</a></li><li><a href=\"https://www.uptodate.com/contents/acyclovir-an-overview/abstract/27\" class=\"nounderline abstract_t\">Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 2010; 304:859.</a></li><li class=\"breakAll\">pregnancyregistry.gsk.com/acyclovir.html (Accessed on September 25, 2012).</li><li class=\"breakAll\">American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. http://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).</li><li class=\"breakAll\">US Food and Drug Administration. Current Drug Shortages. http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).</li><li class=\"breakAll\">American Academy of Pediatrics. Red Book Online. Antiviral recommendations for herpes simplex virus (HSV) and varicella zoster virus (vzv) infections in hospitalized pediatric patients during the intravenous acyclovir shortage. http://aapredbook.aappublications.org/site/news/acyclovir.xhtml (Accessed on December 04, 2012).</li></ol></div><div id=\"topicVersionRevision\">Topic 8332 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H28068474\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISM OF ACTION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Spectrum of activity</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Mechanism of resistance</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">BASIC PHARMACOKINETICS</a></li><li><a href=\"#H20908114\" id=\"outline-link-H20908114\">DOSE ADJUSTMENTS</a><ul><li><a href=\"#H20908121\" id=\"outline-link-H20908121\">Reduced renal function</a></li><li><a href=\"#H20908170\" id=\"outline-link-H20908170\">Obesity</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">TOXICITY</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Acute renal failure</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Neurologic toxicity</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">USE IN PREGNANCY</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">USE OF ACYCLOVIR IN IMMUNOCOMPETENT PATIENTS</a></li><li><a href=\"#H620875503\" id=\"outline-link-H620875503\">IF THERE IS AN ACYCLOVIR SHORTAGE</a><ul><li><a href=\"#H693179357\" id=\"outline-link-H693179357\">Overview of alternative agents</a></li><li><a href=\"#H273810246\" id=\"outline-link-H273810246\">Management of clinical conditions when IV acyclovir is unavailable</a></li></ul></li><li><a href=\"#H28068474\" id=\"outline-link-H28068474\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8332|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/50021\" class=\"graphic graphic_table\">- Drug ratings in pregnancy (US Food and Drug Administration)</a></li></ul></li></ul></div></div><div><h2>CALCULATORS</h2><div id=\"outlineCalculators\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=calculator-ideal-body-weight-method-of-devine-and-dosing-weight-for-adults\" title=\"calculator 1\" class=\"calc calc_professional\">Calculator: Ideal body weight (method of Devine) and dosing weight for adults</a></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=crystal-induced-acute-kidney-injury-acute-renal-failure\" class=\"medical medical_review\">Crystal-induced acute kidney injury (acute renal failure)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=famciclovir-an-overview\" class=\"medical medical_review\">Famciclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=foscarnet-an-overview\" class=\"medical medical_review\">Foscarnet: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ganciclovir-and-valganciclovir-an-overview\" class=\"medical medical_review\">Ganciclovir and valganciclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=herpes-simplex-virus-type-1-encephalitis\" class=\"medical medical_review\">Herpes simplex virus type 1 encephalitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-management-and-prevention\" class=\"medical medical_review\">Neonatal herpes simplex virus infection: Management and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-genital-herpes-simplex-virus-infection\" class=\"medical medical_review\">Treatment of genital herpes simplex virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-varicella-chickenpox-infection\" class=\"medical medical_review\">Treatment of varicella (chickenpox) infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=valacyclovir-an-overview\" class=\"medical medical_review\">Valacyclovir: An overview</a></li></ul></div></div>","javascript":null}